Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Idorsia Ltd
  6. Summary
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
20.32(c) 20.94(c) 21.08(c) 22.04(c) 21.5 Last
1 070 301 937 546 780 266 987 782 218 961 Volume
+1.09% +3.05% +0.67% +4.55% -2.45% Change
More quotes
Estimated financial data (e)
Sales 2021 38,8 M 42,4 M 42,4 M
Net income 2021 -603 M -659 M -659 M
Net Debt 2021 558 M 610 M 610 M
P/E ratio 2021 -6,06x
Yield 2021 -
Sales 2022 113 M 123 M 123 M
Net income 2022 -634 M -693 M -693 M
Net Debt 2022 785 M 858 M 858 M
P/E ratio 2022 -6,12x
Yield 2022 -
Capitalization 3 900 M 4 260 M 4 263 M
EV / Sales 2021 115x
EV / Sales 2022 41,6x
Nbr of Employees 650
Free-Float 65,6%
More Financials
Company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan... 
More about the company
Ratings of Idorsia Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about IDORSIA LTD
01/20Switzerland's Idorsia Wins Japanese Nod For Hemorrhage Drug
MT
01/20Idorsia's Insomnia Drug Shows Improved Sleep Outcomes in Late-Stage Trials
MT
01/20IDORSIA : The Lancet Neurology reports impact of daridorexant on both nighttime symptoms a..
PU
01/12Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day' cam..
GL
01/10GLOBAL MARKETS LIVE : Meta, Goldman Sachs, Novartis, Tesla, Boeing...
01/10Idorsia's insomnia drug gets U.S. FDA approval
RE
01/10Switzerland's Idorsia Wins US FDA Nod for Insomnia Drug
MT
01/10Idorsia's insomnia drug gets U.S. FDA approval
RE
01/10Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first ..
AQ
01/10Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatme..
AQ
01/10Idorsia Receives US FDA Approval of QUVIVIQ (daridorexant) 25 and 50 mg for the Treatme..
CI
2021Idorsia To Push Through Fabry Disease Drug Late-Stage Study
MT
2021Idorsia to Proceed With Late-Stage Study of Lupus Disease Treatment
MT
2021Idorsia to advance cenerimod into Phase 3 development for treatment of patients with sy..
AQ
2021Idorsia Ltd to Advance Cenerimod into Phase 3 Development for Treatment of Patients wit..
CI
More news
News in other languages on IDORSIA LTD
01/20AKTIEN SCHWEIZ SCHLUSS : Leicht fester - Entspannung bei Renditen
01/20BOURSE ZURICH : les indices terminent sur une note positive
01/20Aktien Schweiz drehen ins Plus
01/20BOURSE ZURICH : les indices toujours en repli à l'approche de la mi-journée
01/20Idorsia obtient un feu vert au Japon pour le clazosentan contre le vasospasme
More news
Analyst Recommendations on IDORSIA LTD
More recommendations
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 22,04 CHF
Average target price 27,47 CHF
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
Jean-Paul Clozel Chief Executive Officer & Director
André C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
IDORSIA LTD18.24%4 260
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805